Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: GLS001
MIFTS: 61

Gliosarcoma

Categories: Rare diseases, Cancer diseases, Neuronal diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Gliosarcoma

About this section

MalaCards integrated aliases for Gliosarcoma:

Name: Gliosarcoma 12 72 49 55 51 41 14 69
Glioblastoma with Sarcomatous Component 12
Sarcomatous Glioblastoma 49

Characteristics:

Orphanet epidemiological data:

55
gliosarcoma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 55  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3071
MeSH 41 D018316
NCIt 46 C3796
Orphanet 55 ORPHA251576
UMLS via Orphanet 70 C0206726
ICD10 via Orphanet 33 G71.9
UMLS 69 C0206726
Sources

Summaries for Gliosarcoma

About this section
NIH Rare Diseases : 49 This condition doesn't have a summary yet. Please see our page(s) on Glioblastoma.

MalaCards based summary : Gliosarcoma, also known as glioblastoma with sarcomatous component, is related to glioma susceptibility 1 and anaplastic ganglioglioma, and has symptoms including seizures and headache. An important gene associated with Gliosarcoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are ERK Signaling and PAK Pathway. The drugs Carmustine and Lomustine have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and bone, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 72 Gliosarcoma is a rare type of glioma, a cancer of the brain that comes from glial, or supportive, brain... more...

Sources

Related Diseases for Gliosarcoma

About this section

Diseases related to Gliosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 126)
# Related Disease Score Top Affiliating Genes
1 glioma susceptibility 1 31.0 IDH1 TP53
2 anaplastic ganglioglioma 30.6 GFAP NES
3 ependymoma 30.5 EGFR GFAP MGMT NES
4 glioblastoma 30.5 EGFR FGFR1 IDH1 MGMT PTEN RB1
5 ganglioglioma 30.5 GFAP NES TP53
6 glioma 30.4 EGFR IDH1 PTEN TP53
7 medulloblastoma 30.3 GFAP MGMT NES TP53
8 fibrillary astrocytoma 30.3 GFAP IDH1 MGMT TP53
9 oligodendroglioma 29.9 EGFR GFAP IDH1 MGMT PTEN TP53
10 li-fraumeni syndrome 29.9 EGFR IDH1 PTEN TP53
11 glioblastoma multiforme 29.9 EGFR GFAP IDH1 MGMT NES PPARG
12 astrocytoma 29.8 EGFR FGFR1 GFAP IDH1 MGMT NES
13 squamous cell carcinoma 29.8 EGFR FGFR3 PTEN RB1 TP53
14 pilocytic astrocytoma 29.8 FGFR1 GFAP IDH1 MGMT PTEN
15 giant cell glioblastoma 27.8 EGFR FGFR1 FGFR3 GFAP IDH1 LZTR1
16 adult brainstem gliosarcoma 12.0
17 frontal convexity meningioma 10.8 GFAP TP53
18 gliofibroma 10.8 GFAP TP53
19 oligoastrocytoma 10.8 GFAP MGMT
20 central nervous system teratoma 10.7 GFAP NES
21 central nervous system primitive neuroectodermal neoplasm 10.7 GFAP NES TP53
22 ependymoblastoma 10.7 GFAP NES TP53
23 cerebral convexity meningioma 10.7 GFAP TP53
24 brain ependymoma 10.7 EGFR TP53
25 protoplasmic astrocytoma 10.7 GFAP TP53
26 optic nerve glioma 10.7 GFAP NES TP53
27 retinal cancer 10.7 CCND3 RB1 TP53
28 splenic diffuse red pulp small b-cell lymphoma 10.7 CCND3 TP53
29 sensory system cancer 10.7 CCND3 RB1 TP53
30 infratentorial cancer 10.7 GFAP NES TP53
31 ocular cancer 10.7 CCND3 RB1 TP53
32 cellular ependymoma 10.7 GFAP TP53
33 nervous system cancer 10.6 GFAP RB1 TP53
34 extraventricular neurocytoma 10.6 GFAP IDH1
35 intracranial chondrosarcoma 10.6 IDH1 TP53
36 mixed glioma 10.6 GFAP IDH1 TP53
37 adult medulloblastoma 10.6 GFAP IDH1 TP53
38 cerebellar astrocytoma 10.6 IDH1 TP53
39 dysembryoplastic neuroepithelial tumor 10.6 GFAP IDH1 NES
40 non-invasive bladder papillary urothelial neoplasm 10.6 FGFR3 TP53
41 bladder urothelial carcinoma 10.5 FGFR3 RB1 TP53
42 anaplastic oligodendroglioma 10.5 EGFR IDH1 MGMT
43 pleomorphic xanthoastrocytoma 10.5 GFAP IDH1 MGMT TP53
44 spinal cord astrocytoma 10.5 GFAP IDH1 MGMT TP53
45 plagiocephaly 10.5 FGFR1 FGFR3
46 adult oligodendroglioma 10.5 FGFR1 IDH1
47 brain glioma 10.5 EGFR GFAP MGMT NES TP53
48 osteochondroma 10.5 FGFR1 FGFR3 NES
49 liposarcoma 10.5 PPARG RB1 TP53
50 melanoma, cutaneous malignant 1 10.5 MGMT PTEN TP53

Graphical network of the top 20 diseases related to Gliosarcoma:



Diseases related to Gliosarcoma
Sources

Symptoms & Phenotypes for Gliosarcoma

About this section

UMLS symptoms related to Gliosarcoma:


seizures, headache

GenomeRNAi Phenotypes related to Gliosarcoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.55 EGFR
2 Decreased viability GR00173-A 9.55 PIK3R2
3 Decreased viability GR00221-A-1 9.55 PPARG EGFR FGFR1 FGFR3 PIK3R2
4 Decreased viability GR00221-A-2 9.55 PPARG FGFR1 FGFR3 PIK3R2
5 Decreased viability GR00221-A-3 9.55 PPARG FGFR3
6 Decreased viability GR00221-A-4 9.55 PPARG EGFR PIK3R2
7 Decreased viability GR00301-A 9.55 PIK3R2

MGI Mouse Phenotypes related to Gliosarcoma:

43 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.45 PPARG RB1 PTEN PIK3R2 TP53 SNAI2
2 homeostasis/metabolism MP:0005376 10.42 PPARG RB1 NFKBIA PTEN PIK3R2 SNAI2
3 mortality/aging MP:0010768 10.38 PPARG RB1 PTEN TP53 SNAI2 TACC3
4 hematopoietic system MP:0005397 10.37 PPARG NFKBIA PTEN SNAI2 TP53 RB1
5 cardiovascular system MP:0005385 10.35 PTEN PPARG PIK3R2 SNAI2 RB1 TP53
6 immune system MP:0005387 10.35 PPARG NFKBIA PTEN SNAI2 TP53 RB1
7 endocrine/exocrine gland MP:0005379 10.32 PPARG NFKBIA PTEN SNAI2 TP53 RB1
8 embryo MP:0005380 10.24 PTEN PPARG TACC3 SNAI2 RB1 TP53
9 integument MP:0010771 10.22 PPARG NFKBIA PTEN SNAI2 TP53 RB1
10 craniofacial MP:0005382 10.21 SNAI2 RB1 TACC3 TP53 FGFR1 EGFR
11 digestive/alimentary MP:0005381 10.2 PTEN RB1 SNAI2 TP53 FGFR1 EGFR
12 normal MP:0002873 10.14 PPARG RB1 NFKBIA PTEN TP53 TACC3
13 neoplasm MP:0002006 10.13 RB1 PTEN PIK3R2 PPARG TP53 TACC3
14 hearing/vestibular/ear MP:0005377 10.11 PPARG RB1 TP53 FGFR1 EGFR FREM2
15 limbs/digits/tail MP:0005371 10.11 PTEN RB1 TACC3 TP53 FGFR1 EGFR
16 muscle MP:0005369 10.11 PTEN PPARG PIK3R2 RB1 TP53 FGFR1
17 liver/biliary system MP:0005370 10.04 PTEN PPARG TACC3 RB1 TP53 EGFR
18 renal/urinary system MP:0005367 9.92 PTEN PPARG RB1 TP53 FGFR1 EGFR
19 reproductive system MP:0005389 9.91 PTEN PPARG RB1 SNAI2 TP53 FGFR1
20 pigmentation MP:0001186 9.85 PTEN SNAI2 RB1 TP53 EGFR FREM2
21 respiratory system MP:0005388 9.81 PTEN TP53 RB1 EGFR CCND3 IDH1
22 skeleton MP:0005390 9.7 PPARG PTEN SNAI2 TP53 RB1 TACC3
23 vision/eye MP:0005391 9.36 RB1 PTEN PPARG TP53 SNAI2 EGFR
Sources

Drugs & Therapeutics for Gliosarcoma

About this section

Drugs for Gliosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 399)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carmustine Approved, Investigational Phase 3,Phase 2,Phase 1 154-93-8 2578
2
Lomustine Approved, Investigational Phase 3,Phase 1 13010-47-4 3950
3
Procarbazine Approved, Investigational Phase 3,Phase 1,Phase 2 671-16-9 4915
4
Trioxsalen Approved Phase 3,Phase 1 3902-71-4 5585
5
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
6
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
7
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
8
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
9
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
10
Vincristine Approved, Investigational Phase 3,Phase 1,Phase 2 2068-78-2, 57-22-7 5978
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Methylphenidate Approved, Investigational Phase 3 20748-11-2, 113-45-1 4158
13
Morphine Approved, Investigational Phase 3 57-27-2 5288826
14
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
15
Isotretinoin Approved Phase 3,Phase 2,Phase 1 4759-48-2 5282379 5538
16
Dopamine Approved Phase 3,Phase 1 51-61-6, 62-31-7 681
17
Cyproheptadine Approved Phase 3 129-03-3 2913
18
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
19
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538
20 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
21
Veliparib Investigational Phase 2, Phase 3,Phase 1 912444-00-9 11960529
22 Dianhydrogalactitol Investigational Phase 3 23261-20-3
23 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
24 Dermatologic Agents Phase 3,Phase 1,Phase 2
25 Dihematoporphyrin Ether Phase 3,Phase 1
26 Ether Phase 3
27 Photosensitizing Agents Phase 3,Phase 2,Phase 1
28 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
29 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
30 Antirheumatic Agents Phase 3,Phase 1,Phase 2
31 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
32 Central Nervous System Depressants Phase 3,Phase 2,Phase 1
33 Antimitotic Agents Phase 3,Phase 1,Phase 2
34 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
35 Keratolytic Agents Phase 3,Phase 1,Phase 2
36 O(6)-benzylguanine Phase 3,Phase 2,Phase 1
37 Antibodies Phase 3,Phase 2,Phase 1
38 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
39 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
40 Immunoglobulins Phase 3,Phase 2,Phase 1
41 Mitogens Phase 3,Phase 1,Phase 2
42 Anesthetics Phase 3,Phase 1
43 Anesthetics, General Phase 3
44 Anesthetics, Inhalation Phase 3
45 Hematoporphyrin Derivative Phase 3
46 Hematoporphyrins Phase 3
47 Adjuvants, Anesthesia Phase 3
48 Analgesics Phase 3,Phase 2,Phase 1
49 Analgesics, Opioid Phase 3
50 Anesthetics, Intravenous Phase 3

Interventional clinical trials:

(show top 50) (show all 470)

# Name Status NCT ID Phase Drugs
1 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
2 S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
3 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
4 Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Completed NCT00884741 Phase 3 Temozolomide
5 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Completed NCT01480479 Phase 3 Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
6 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3 temozolomide
7 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00482677 Phase 3 temozolomide
8 Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme Completed NCT00002545 Phase 3 carmustine
9 Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00006353 Phase 3 temozolomide
10 SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
11 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
12 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3 porfimer sodium
13 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
14 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
15 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919 Phase 3
16 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
17 A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification Recruiting NCT02573324 Phase 3 Temozolomide;ABT-414;Placebo for ABT-414
18 Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Recruiting NCT02152982 Phase 2, Phase 3 Temozolomide;Veliparib
19 VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM Active, not recruiting NCT03149575 Phase 3 VAL-083, Dianhydrogalactitol;Physician's Choice of Salvage Therapy - temozolomide;Physician's Choice of Salvage Therapy - lomustine;Physician's Choice of Salvage Therapy - carboplatin
20 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
21 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
22 Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
23 Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma Unknown status NCT01124539 Phase 2 AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin)
24 Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Unknown status NCT01013285 Phase 2 temozolomide
25 Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma Unknown status NCT00936052 Phase 2
26 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
27 Hydroxychloroquine, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Unknown status NCT00486603 Phase 1, Phase 2 hydroxychloroquine;temozolomide
28 Radiation Therapy Plus Hyperbaric Oxygen in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Unknown status NCT00006460 Phase 1, Phase 2 hyperbaric oxygen
29 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma Unknown status NCT00114309 Phase 2 131-I-TM-601;131I-TM601
30 Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas Unknown status NCT00492687 Phase 2 carboplatin;tamoxifen citrate;temozolomide
31 Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme Unknown status NCT00014105 Phase 1, Phase 2 carboplatin;temozolomide
32 Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme Unknown status NCT00054496 Phase 2 erlotinib hydrochloride
33 Carmustine in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Unknown status NCT00006656 Phase 2 carmustine in ethanol
34 Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma Unknown status NCT00003176 Phase 2 carmustine;temozolomide
35 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
36 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
37 Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma Completed NCT00525525 Phase 2 Bevacizumab;Tarceva;Temozolomide
38 Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas Completed NCT00612339 Phase 2 Avastin and Temozolomide
39 Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Completed NCT00335764 Phase 1, Phase 2 sorafenib tosylate;erlotinib hydrochloride;tipifarnib;temsirolimus
40 Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas Completed NCT00597402 Phase 2 Avastin;Temozolomide;Irinotecan
41 Phase 1/2 Study in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients Completed NCT00402116 Phase 1, Phase 2 enzastaurin;temozolomide
42 Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors Completed NCT00187486 Phase 2 Tarceva;Temodar
43 Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma Completed NCT00433381 Phase 2 irinotecan hydrochloride;temozolomide
44 Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Completed NCT00305864 Phase 1, Phase 2 Motexafin Gadolinium;Temozolomide
45 Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme Completed NCT00979017 Phase 2 Avastin;Temozolomide;Irinotecan
46 Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00165477 Phase 2 lenalidomide
47 Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme Completed NCT00883298 Phase 2 temozolomide and bevacizumab
48 AMG 102 and Avastin for Recurrent Malignant Glioma Completed NCT01113398 Phase 2 AMG 102;Avastin
49 Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma Completed NCT00028795 Phase 2 temozolomide
50 BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) Completed NCT01856933 Phase 2 PSMA ADC

Search NIH Clinical Center for Gliosarcoma

Cochrane evidence based reviews: gliosarcoma

Sources

Genetic Tests for Gliosarcoma

About this section
Sources

Anatomical Context for Gliosarcoma

About this section

MalaCards organs/tissues related to Gliosarcoma:

38
Brain, T Cells, Bone, Bone Marrow, Prostate, Liver, Spinal Cord
Sources

Publications for Gliosarcoma

About this section

Articles related to Gliosarcoma:

(show top 50) (show all 367)
# Title Authors Year
1
Treatment-associated<i>TP53</i>DNA-binding domain missense mutations in the pathogenesis of secondary gliosarcoma. ( 29416795 )
2018
2
High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients. ( 28408749 )
2017
3
Functional and morphological effects of diazepam and midazolam on tumor vasculature in the 9L gliosarcoma brain tumor model using dynamic susceptibility contrast MRI: a comparative study. ( 29042753 )
2017
4
Gliosarcomas with the BRAF V600E mutation: a report of two cases and review of the literature. ( 28775171 )
2017
5
Gliosarcoma in septuagenarians and octogenarians: What is the impact of adjuvant chemoradiation? ( 28756069 )
2017
6
Intraventricular gliosarcoma with dual sarcomatous differentiation: A unique case. ( 28261869 )
2017
7
Lateral ventricular gliosarcoma with attachment to septum pellucidum. ( 28413542 )
2017
8
Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database. ( 28621623 )
2017
9
Gliosarcoma in Young Adults: A Rare Variant of Glioblastoma. ( 29147435 )
2017
10
Glioblastoma recurrence, progression, and dissemination as a purely subdural gliosarcoma. ( 28290000 )
2017
11
Analysis of outcomes of multidisciplinary management of Gliosarcoma: a single centre study, 2000-2013. ( 28642179 )
2017
12
The endothelial prostate-specific membrane antigen is highly expressed in gliosarcoma and visualized by [68Ga]-PSMA-11 PET: a theranostic outlook for brain tumor patients? ( 29045711 )
2017
13
Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted. ( 28812310 )
2017
14
Photodithazine photodynamic effect on viability of 9L/lacZ gliosarcoma cell line. ( 28503718 )
2017
15
Detailed magnetic resonance imaging features of a case series of primary gliosarcoma. ( 28644110 )
2017
16
Reproducibility and relative stability in magnetic resonance imaging indices of tumor vascular physiology over a period of 24h in a rat 9L gliosarcoma model. ( 28887206 )
2017
17
Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma. ( 29264835 )
2017
18
Primary gliosarcoma: epidemiology, clinical presentation, management and survival. ( 29154508 )
2017
19
Primary Multifocal Gliosarcoma of the Spinal Cord. ( 27134708 )
2016
20
Concurrent Gliosarcoma and Choroid Plexus Carcinoma in a Cow. ( 27899174 )
2016
21
Gliosarcoma with Primary Skull Base Invasion. ( 28053799 )
2016
22
Radiotherapy plus concomitant temozolomide in primary gliosarcoma. ( 27025857 )
2016
23
Dural and osteolytic sarcomatoid relapse of a secondary gliosarcoma with tryptase immunoreactivity. ( 26784965 )
2016
24
A Stable Secondary Gliosarcoma with Extensive Systemic Metastases: A Case Report. ( 27867925 )
2016
25
Post-Treatment Gliosarcoma Extension into the Pterygomaxillary Fossa: Literature Review and Case Report. ( 27699141 )
2016
26
Metastatic Gliosarcoma: Cytopathologic Characteristics with Histopathologic Correlations. ( 27584833 )
2016
27
An IDH1-mutated primary gliosarcoma: case report. ( 27153165 )
2016
28
Evolution of DNA aptamers for malignant brain tumor gliosarcoma cell recognition and clinical tissue imaging. ( 26802746 )
2016
29
Brain tumors in Li-Fraumeni syndrome: a commentary and a case of a gliosarcoma patient. ( 27523101 )
2016
30
Gliosarcoma: A rare variant of glioblastoma multiforme in paediatric patient: Case report and review of literature. ( 27672648 )
2016
31
Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. ( 27314913 )
2016
32
Gliosarcoma with a primitive neuroectodermal tumour component. ( 27772848 )
2016
33
Gliosarcoma with smooth muscle cell differentiation: a case report. ( 27704522 )
2016
34
Temporal Lobe Gliosarcoma After Gamma Knife Radiosurgery for Vestibular Schwannoma. ( 27309712 )
2016
35
Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients. ( 26725096 )
2016
36
Evaluation of Antitumor Activity of Long-Circulating and pH-Sensitive Liposomes Containing Ursolic Acid in Animal Models of Breast Tumor and Gliosarcoma. ( 27130721 )
2016
37
Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. ( 27231756 )
2016
38
Gliosarcomas lack BRAF(V600E) mutation, but a subset exhibit I^-catenin nuclear localization. ( 26932501 )
2016
39
Primary Gliosarcoma of the Optic Nerve: A Unique Adult Optic Pathway Glioma. ( 27792048 )
2016
40
Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series. ( 27169763 )
2016
41
Gliosarcoma in the Cerebellopontine Angle with Rapid Tumor Growth and Intratumoral Hemorrhage. ( 27338213 )
2016
42
An individual patient data meta-analysis on characteristics, treatments and outcomes of glioblastoma/ gliosarcoma patients with metastases outside of the central nervous system. ( 25860797 )
2015
43
Therapeutic management of gliosarcoma in the temozolomide era. ( 25905568 )
2015
44
Gliosarcoma with leiomyomatous differentiation: A case report with an emphasis on histogenesis. ( 26881542 )
2015
45
Primary Cerebellar Gliosarcoma with Extracranial Metastases: An Orphan Differential Diagnosis. ( 26239018 )
2015
46
Long-term survival in gliosarcoma with radiation-induced meningeal sarcomas: Case report and molecular features. ( 26458625 )
2015
47
Assessing Amide Proton Transfer (APT) MRI Contrast Origins in 9A L Gliosarcoma in the Rat Brain Using Proteomic Analysis. ( 25622812 )
2015
48
Cerebral gliosarcoma: Analysis of 16 patients and review of literature. ( 26396606 )
2015
49
Gliosarcoma with neuroaxis metastases. ( 26621904 )
2015
50
Genetic alterations in gliosarcoma and giant cell glioblastoma. ( 26443480 )
2015
Sources

Variations for Gliosarcoma

About this section

Cosmic variations for Gliosarcoma:

9 (show all 11)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA Conf
1 COSM10893 TP53 central nervous system,brain,glioma,gliosarcoma c.824G>A p.C275Y 6
2 COSM10648 TP53 central nervous system,brain,glioma,gliosarcoma c.524G>A p.R175H 6
3 COSM5123 PTEN central nervous system,brain,glioma,gliosarcoma c.395G>A p.G132D 6
4 COSM5308 PTEN central nervous system,brain,glioma,gliosarcoma c.565A>T p.R189* 6
5 COSM5154 PTEN central nervous system,brain,glioma,gliosarcoma c.697C>T p.R233* 6
6 COSM5191 PTEN central nervous system,brain,glioma,gliosarcoma c.198G>T p.K66N 6
7 COSM5152 PTEN central nervous system,brain,glioma,gliosarcoma c.388C>T p.R130* 6
8 COSM5033 PTEN central nervous system,brain,glioma,gliosarcoma c.389G>A p.R130Q 6
9 COSM22413 PDGFRA central nervous system,brain,glioma,gliosarcoma c.2472C>T p.V824V 6
10 COSM564 NRAS central nervous system,brain,glioma,gliosarcoma c.35G>A p.G12D 6
11 COSM476 BRAF central nervous system,brain,glioma,gliosarcoma c.1799T>A p.V600E 6
Sources

Expression for Gliosarcoma

About this section
Search GEO for disease gene expression data for Gliosarcoma.
Sources

Pathways for Gliosarcoma

About this section

Pathways related to Gliosarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 60
Show member pathways
 13.85 CCND3 EGFR FGFR1 FGFR3 NFKBIA PIK3R2
2
PAK Pathway 60
Show member pathways
 13.32 EGFR FGFR1 FGFR3 NFKBIA PIK3R2 PTEN
3
GAB1 signalosome 62
Show member pathways
 13.13 EGFR FGFR1 FGFR3 PIK3R2 PTEN TP53
4
Phospholipase-C Pathway 60
Show member pathways
 13.08 EGFR FGFR1 FGFR3 PIK3R2 PTEN TP53
5
Endometrial cancer 36
Show member pathways
 12.9 EGFR FGFR1 FGFR3 NFKBIA PIK3R2 PPARG
6
PI3K-Akt signaling pathway 36
Show member pathways
 12.88 CCND3 EGFR FGFR1 FGFR3 PIK3R2 PTEN
7
Gastric cancer 36
Show member pathways
 12.75 EGFR FGFR1 PIK3R2 PTEN RB1 TP53
8
NF-KappaB Family Pathway 60
Show member pathways
 12.71 EGFR FGFR1 FGFR3 NFKBIA PIK3R2
9
Development Endothelin-1/EDNRA signaling 21
Show member pathways
 12.68 CCND3 EGFR NFKBIA PIK3R2 PTEN
10
4-1BB Pathway 60
Show member pathways
 12.68 EGFR NFKBIA PIK3R2 RB1 TP53
11
Downstream signaling events of B Cell Receptor (BCR) 62
Show member pathways
 12.66 EGFR FGFR1 FGFR3 NFKBIA PIK3R2 PTEN
12
Relaxin signaling pathway 36
Show member pathways
 12.58 EGFR NFKBIA PIK3R2 RB1 TP53
13
Kaposi's sarcoma-associated herpesvirus infection 36
Show member pathways
 12.58 NFKBIA PIK3R2 PTEN RB1 TP53
14
MicroRNAs in cancer 36
12.52 EGFR FGFR3 PIK3R2 PTEN TP53
15
DNA Damage 4
12.51 CCND3 MGMT RB1 TACC3 TP53
16
Development EGFR signaling pathway 21
Show member pathways
 12.5 EGFR NFKBIA PIK3R2 TP53
17
mTOR signaling pathway (KEGG) 61
Show member pathways
 12.46 EGFR FGFR1 FGFR3 PIK3R2 PTEN TP53
18
HTLV-I infection 36
12.42 CCND3 NFKBIA PIK3R2 RB1 TP53
19
RhoGDI Pathway 60
Show member pathways
 12.4 EGFR FGFR1 FGFR3 PIK3R2
20
Apoptosis Pathway 68
Show member pathways
 12.39 EGFR FGFR1 FGFR3 NFKBIA PIK3R2 TP53
21
DNA Damage Response 1
Show member pathways
 12.38 CCND3 PTEN RB1 TP53
22
Development IGF-1 receptor signaling 21
Show member pathways
 12.38 CCND3 NFKBIA PIK3R2 PTEN TP53
23
Pathways in cancer 36
12.38 CCND3 EGFR FGFR1 FGFR3 NFKBIA PIK3R2
24
Jak-STAT signaling pathway (KEGG) 36
Show member pathways
 12.37 CCND3 EGFR GFAP PIK3R2
25
Epstein-Barr virus infection 36
12.31 NFKBIA PIK3R2 RB1 TP53
26
Proteoglycans in cancer 36
12.31 EGFR FGFR1 PIK3R2 TP53
27
Viral carcinogenesis 36
12.28 CCND3 NFKBIA PIK3R2 RB1 TP53
28
G-protein signaling Ras family GTPases in kinase cascades (scheme) 21
Show member pathways
 12.27 NFKBIA PIK3R2 PPARG TP53
29
VEGF Signaling Pathway 63 57
Show member pathways
 12.24 EGFR FGFR1 FGFR3 PTEN
30
Cellular senescence (KEGG) 36
12.16 CCND3 PIK3R2 PTEN RB1 TP53
31
Development EGFR signaling via small GTPases 21
Show member pathways
 12.15 EGFR NFKBIA PIK3R2 PTEN
32
Integrated Breast Cancer Pathway 1
12.13 EGFR PIK3R2 PTEN RB1 TP53
33
Chronic myeloid leukemia 36
Show member pathways
 12.12 EGFR NFKBIA PIK3R2 RB1 TP53
34
p53 Pathway (RnD) 61
12.08 CCND3 MGMT PTEN TP53
35
Hepatitis C 36
12.07 EGFR NFKBIA PIK3R2 TP53
36
MAPK Pathway 68
Show member pathways
 12.03 EGFR NFKBIA PIK3R2 TP53
37
Direct p53 effectors 1
12.03 EGFR PTEN RB1 SNAI2 TP53
38
Spinal Cord Injury 1
12.01 EGFR GFAP RB1 TP53
39
DNA Damage Response (only ATM dependent) 1
11.98 CCND3 PIK3R2 PTEN TP53
40
MAPK Signaling: Mitogen Stimulation Pathway 61
Show member pathways
 11.94 CCND3 EGFR FGFR1 FGFR3 PIK3R2 PTEN
41
Neural Crest Differentiation 1
11.91 FGFR1 FGFR3 GFAP SNAI2
42
Androgen receptor signaling pathway 1
11.85 EGFR PIK3R2 PTEN RB1
43
Retinoblastoma (RB) in Cancer 1
11.84 CCND3 RB1 TP53
44
Glioblastoma Multiforme 60
11.78 EGFR MGMT PIK3R2 PTEN RB1 TP53
45
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 61
11.77 FGFR1 FGFR3 GFAP NES
46
Small cell lung cancer 36
11.77 NFKBIA PIK3R2 PTEN RB1 TP53
47
Adherens junction 36
11.74 EGFR FGFR1 SNAI2
48
Human Thyroid Stimulating Hormone (TSH) signaling pathway 1
11.71 CCND3 PIK3R2 RB1
49
IL-2 Gene Expression in Activated and Quiescent T-Cells 60
Show member pathways
 11.62 EGFR NFKBIA PIK3R2 RB1
50
Bladder cancer 36 1
11.58 EGFR FGFR3 PIK3R2 RB1 TP53
Sources

GO Terms for Gliosarcoma

About this section

Cellular components related to Gliosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.5 CCND3 EGFR FGFR1 FGFR3 GFAP IDH1

Biological processes related to Gliosarcoma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.97 CCND3 FGFR1 PPARG RB1 SNAI2 TP53
2 cell cycle GO:0007049 9.88 CCND3 RB1 SEPT14 TACC1 TACC3 TP53
3 cell division GO:0051301 9.85 CCND3 RB1 SEPT14 TACC1 TACC3
4 regulation of cell proliferation GO:0042127 9.84 CCND3 EGFR FGFR1 NFKBIA
5 cell proliferation GO:0008283 9.83 EGFR PTEN TACC1 TACC3 TP53
6 cellular response to insulin stimulus GO:0032869 9.73 PIK3R2 PPARG PTEN
7 negative regulation of apoptotic process GO:0043066 9.73 EGFR MGMT NFKBIA PTEN SNAI2 TP53
8 positive regulation of protein kinase B signaling GO:0051897 9.62 EGFR FGFR1 FGFR3 PIK3R2
9 response to lipid GO:0033993 9.58 EGFR PPARG
10 white fat cell differentiation GO:0050872 9.58 PPARG SNAI2
11 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.57 NFKBIA PPARG
12 response to caffeine GO:0031000 9.55 PPARG TP53
13 phosphatidylinositol-3-phosphate biosynthetic process GO:0036092 9.54 FGFR1 FGFR3 PIK3R2
14 negative regulation of telomerase activity GO:0051974 9.52 PPARG TP53
15 salivary gland morphogenesis GO:0007435 9.51 EGFR FGFR1
16 positive regulation of phospholipase activity GO:0010518 9.48 FGFR1 FGFR3
17 cellular response to ionizing radiation GO:0071479 9.33 MGMT SNAI2 TP53
18 phosphatidylinositol phosphorylation GO:0046854 9.26 EGFR FGFR1 FGFR3 PIK3R2
19 response to organic cyclic compound GO:0014070 9.1 EGFR IDH1 MGMT PPARG PTEN TP53

Molecular functions related to Gliosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.73 EGFR NFKBIA PPARG PTEN RB1 TP53
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.58 EGFR FGFR1 FGFR3
3 1-phosphatidylinositol-3-kinase activity GO:0016303 9.5 FGFR1 FGFR3 PIK3R2
4 protein phosphatase binding GO:0019903 9.46 EGFR PIK3R2 PPARG TP53
5 fibroblast growth factor-activated receptor activity GO:0005007 9.37 FGFR1 FGFR3
6 identical protein binding GO:0042802 9.32 EGFR FGFR1 FGFR3 GFAP IDH1 NFKBIA
7 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.26 EGFR FGFR1 FGFR3 PIK3R2
Sources

Sources for Gliosarcoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....